skip to main content

Kawasaki Disease — MRCP Part 1 MCQ

Instant feedback + full explanation. One question, done properly.

HardPaediatricsKawasaki DiseaseMRCP Part 1MRCEM SBAUKMLA

At week 24 of deucravacitinib for plaque psoriasis, PASI has improved by 58% and DLQI by 3 points from baseline. Which decision follows TA907?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Consider stopping because week-24 response criteria are unmet

The best answer is “Consider stopping because week-24 response criteria are unmet”. At week 24, adequate response is PASI 75, or PASI 50 plus a 5-point DLQI fall. PASI 58 with only 3 DLQI points meets neither definition. The earlier 16-to-24-week rule also permits stopping without PASI 50.

Reference: NICE TA907, Deucravacitinib for moderate to severe plaque psoriasis: https://www.nice.org.uk/guidance/ta907/chapter/1-Recommendations